Orexo AB | Balance Sheet

Fiscal year is January-December. All values SEK Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
106
284
198
282
328
590
Total Accounts Receivable
50
170
215
203
226
270
Inventories
383
478
403
344
250
174
Other Current Assets
6
4
4
4
24
26
Total Current Assets
544
936
820
834
827
1,060
Net Property, Plant & Equipment
33
29
25
22
20
20
Total Investments and Advances
-
1
2
-
7
-
Intangible Assets
195
259
156
138
121
104
Total Assets
772
1,226
1,020
1,019
1,004
1,287
ST Debt & Current Portion LT Debt
137
2
-
-
-
Accounts Payable
138
29
35
36
46
Income Tax Payable
3
3
-
-
-
Other Current Liabilities
219
234
214
274
304
Total Current Liabilities
497
268
249
310
350
Long-Term Debt
104
494
494
398
319
Provision for Risks & Charges
10
9
7
1
6
Deferred Taxes
-
-
18
25
28
Total Liabilities
611
771
750
709
675
Common Equity (Total)
161
455
270
310
329
Total Shareholders' Equity
161
455
270
310
329
Total Equity
161
455
270
310
329
Liabilities & Shareholders' Equity
772
1,226
1,020
1,019
1,004

About Orexo AB

View Profile
Address
Rapsgatan 7e
Uppsala UP 751 05
Sweden
Employees -
Website http://www.orexo.com
Updated 07/08/2019
Orexo AB engages in the development of pharmaceuticals based on innovative drug delivery technologies. Its focuses on the treatment of opioid dependence. Its pipeline comprises of Zubsolv, Abstral, Edluar, Zubsolv, OX51, OX-MP1, and OX382.